BioLife Solutions, Inc.

Valuation Analysis

About the Company

BioLife Solutions, Inc. develops, manufactures, and markets bioproduction products and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies. It offers proprietary biopreservation media products, including HypoThermosol FRS and CryoStor Freeze Media that are formulated to mitigate preservation-induced, delayed-onset cell damage and death; bioproduction products, such as human platelet lysates for cell expansion and CellSeal closed system vials that are used in CGT; CryoCase cryo-compatible transparent rigid containers for closed-system fill and retrieval, and automated cell processing machines

BioLife Solutions, Inc. Stock at a Glance

BioLife Solutions, Inc. (BLFS) is currently trading at $26.10 with a market capitalization of $1.3B. The 52-week range spans from $17.86 to $29.62; the current price is 11.9% below the yearly high. Year-over-year revenue growth stands at +24.7%.

💰 Dividend

BioLife Solutions, Inc. currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.

📊 Analyst Rating

10 analysts rate BioLife Solutions, Inc. (BLFS) on consensus: Strong Buy. The average price target is $32.30, implying +23.75% from the current price. Analyst price targets range from $30.00 to $34.00.

BioLife Solutions, Inc.: The Investment Case in Detail

BioLife Solutions, Inc. (BLFS) operates in the Healthcare — specifically Medical Instruments & Supplies — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.

The Bull Case

Revenue is growing at a healthy 24.7% pace year-over-year, suggesting the business model continues to find new customers and pricing power. With a gross margin near 63.76%, the company sits in the top tier of its industry — these are the kinds of structural margins that protect earnings during downturns. Wall Street consensus sits at Strong Buy with an average price target implying roughly 23.75% upside from current levels — analyst sentiment is firmly constructive.

The Bear Case

Net margins remain negative, meaning every euro of revenue is still producing losses — the path to profitability is the central question for shareholders. With a beta near 1.97, the share price moves sharply more than the broader market — drawdowns in market corrections can be unusually severe and require strong nerves. Short interest sits at 12.74% of float — a meaningful contingent of professionals is positioned for the share to fall, which deserves attention even if their thesis may turn out to be wrong.

Valuation in Context

At a PEG of 15.09, investors are paying more than three times the growth rate for each unit of earnings — that pricing assumes growth not only continues but accelerates from here. The EV/EBITDA multiple of 279.81x reflects rich expectations — historically, multiples at this level have proven hard to maintain for more than a few quarters.

What to Watch Next

• The analyst consensus price target implies 23.75% upside — if the next two quarters confirm the underlying thesis, target hikes typically follow.

Investment Thesis: Strengths & Weaknesses

Technical Snapshot

The price is in a transition zone relative to the moving averages — no clear signal.

Risk Profile

The data points to above-average price swings, elevated short interest (12.74%).

Trading Data

Related Stocks in the Same Sector

Where can I buy BioLife Solutions, Inc.?

Compare top-rated brokers — low fees, trusted providers, fully regulated.